Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2021 - 2026)

Oramed Pharmaceuticals has reported Other Accumulated Expenses for 6 years, with the latest figure at $285000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $285000.0; the trailing twelve-month figure through Mar 2026 stood at $285000.0 (changed N/A YoY), and the FY2025 full-year result was $633000.0, up 87.28% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $285000.0, down from $633000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $633000.0 in Q4 2025, with the low at $59000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $185750.0 across 5 years, with a median of $133000.0 in 2022.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 55.64% — and 2024, when it jumped 472.88%.
• Oramed Pharmaceuticals' Other Accumulated Expenses stood at $133000.0 in 2022, then plunged by 55.64% to $59000.0 in 2023, then jumped by 472.88% to $338000.0 in 2024, then surged by 87.28% to $633000.0 in 2025, then plunged by 54.98% to $285000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $285000.0 (Q1 2026), $633000.0 (Q4 2025), and $338000.0 (Q4 2024), per Business Quant data.